MX2016014414A - Vacuna de peptido que comprende un peptido ras mutante y un agente quimioterapeutico. - Google Patents
Vacuna de peptido que comprende un peptido ras mutante y un agente quimioterapeutico.Info
- Publication number
- MX2016014414A MX2016014414A MX2016014414A MX2016014414A MX2016014414A MX 2016014414 A MX2016014414 A MX 2016014414A MX 2016014414 A MX2016014414 A MX 2016014414A MX 2016014414 A MX2016014414 A MX 2016014414A MX 2016014414 A MX2016014414 A MX 2016014414A
- Authority
- MX
- Mexico
- Prior art keywords
- peptide
- chemotherapeutic agent
- mutant ras
- vaccine
- cancer
- Prior art date
Links
- 239000002246 antineoplastic agent Substances 0.000 title abstract 2
- 229940127089 cytotoxic agent Drugs 0.000 title abstract 2
- 108010014186 ras Proteins Proteins 0.000 title abstract 2
- 229940023041 peptide vaccine Drugs 0.000 title 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 3
- 206010028980 Neoplasm Diseases 0.000 abstract 2
- 201000011510 cancer Diseases 0.000 abstract 2
- 230000000340 anti-metabolite Effects 0.000 abstract 1
- 229940100197 antimetabolite Drugs 0.000 abstract 1
- 239000002256 antimetabolite Substances 0.000 abstract 1
- 239000012634 fragment Substances 0.000 abstract 1
- 230000028993 immune response Effects 0.000 abstract 1
- 230000035772 mutation Effects 0.000 abstract 1
- 102000016914 ras Proteins Human genes 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001154—Enzymes
- A61K39/001164—GTPases, e.g. Ras or Rho
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/82—Translation products from oncogenes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55522—Cytokines; Lymphokines; Interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
- A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Oncology (AREA)
- Cell Biology (AREA)
- Engineering & Computer Science (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Virology (AREA)
- Biomedical Technology (AREA)
- Zoology (AREA)
- Developmental Biology & Embryology (AREA)
- Biotechnology (AREA)
- Hematology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP14167265 | 2014-05-06 | ||
| PCT/EP2015/059861 WO2015169804A1 (en) | 2014-05-06 | 2015-05-05 | Peptide vaccine comprising mutant ras peptide and chemotherapeutic agent |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2016014414A true MX2016014414A (es) | 2017-02-23 |
Family
ID=50679896
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2016014414A MX2016014414A (es) | 2014-05-06 | 2015-05-05 | Vacuna de peptido que comprende un peptido ras mutante y un agente quimioterapeutico. |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US9757439B2 (https=) |
| EP (1) | EP3140320B1 (https=) |
| JP (2) | JP2017514847A (https=) |
| KR (1) | KR20170002563A (https=) |
| CN (1) | CN106414493A (https=) |
| AU (1) | AU2015257774B2 (https=) |
| BR (1) | BR112016025764A2 (https=) |
| CA (1) | CA2947963A1 (https=) |
| CL (1) | CL2016002794A1 (https=) |
| DK (1) | DK3140320T3 (https=) |
| ES (1) | ES2716923T3 (https=) |
| IL (1) | IL248671B (https=) |
| MX (1) | MX2016014414A (https=) |
| RU (1) | RU2700929C2 (https=) |
| SG (2) | SG11201608712PA (https=) |
| WO (1) | WO2015169804A1 (https=) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3369432A1 (en) | 2013-12-09 | 2018-09-05 | Targovax Asa | A peptide mixture |
| SG11201903674YA (en) | 2016-10-26 | 2019-05-30 | Modernatx Inc | Messenger ribonucleic acids for enhancing immune responses and methods of use thereof |
| JP2020514321A (ja) | 2017-02-01 | 2020-05-21 | モデルナティーエックス， インコーポレイテッド | 活性化がん遺伝子変異ペプチドをコードする免疫調節治療ｍＲＮＡ組成物 |
| WO2018145020A1 (en) * | 2017-02-03 | 2018-08-09 | The Medical College Of Wisconsin, Inc. | Kras peptide vaccine compositions and method of use |
| BR112020025764A2 (pt) | 2018-06-19 | 2021-05-11 | Biontech Us Inc. | neoantígenos e usos dos mesmos |
| WO2020002650A1 (en) | 2018-06-29 | 2020-01-02 | Targovax Asa | A formulation |
| CN114681600A (zh) * | 2018-10-19 | 2022-07-01 | 杭州纽安津生物科技有限公司 | 通用性多肽疫苗及其在制备治疗/预防胰腺癌药物中的应用 |
| CA3141084A1 (en) * | 2019-06-12 | 2020-12-17 | Vikram JUNEJA | Neoantigen compositions and uses thereof |
| CN113416241B (zh) * | 2020-04-09 | 2022-04-08 | 北京臻知医学科技有限责任公司 | 一种用于诱导肿瘤特异性免疫响应的通用型抗原肽库及试剂盒 |
| WO2022026620A1 (en) * | 2020-07-29 | 2022-02-03 | Sqz Biotechnologies Company | Methods to stimulate immune responses to mutant ras using nucleated cells |
| EP4188425B1 (en) * | 2020-07-29 | 2025-05-14 | Stemcell Technologies Canada Inc. | Methods to stimulate immune responses to mutant ras using anucleate cells |
| US20240000834A1 (en) * | 2020-11-24 | 2024-01-04 | Shanghai GenBase Biotechnology Co., Ltd. | Ras mutant epitope peptide and t cell receptor recognizing ras mutant |
| JP2024541968A (ja) * | 2021-10-28 | 2024-11-13 | ジェネンテック， インコーポレイテッド | 治療的介入のためにｍｈｃ関連抗原を同定するためのシステムおよび方法 |
| WO2023220434A2 (en) * | 2022-05-12 | 2023-11-16 | The Johns Hopkins University | Neoantigen vaccines for cancer prevention |
| WO2025103205A1 (en) * | 2023-11-15 | 2025-05-22 | Ck Life Sciences Development Limited | Pharmaceutical compositions and methods for preventing or treating kras-associated diseases or conditions |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9103974D0 (en) * | 1991-02-26 | 1991-04-10 | Norsk Hydro As | Therapeutically useful peptides or peptide fragments |
| GB2328689A (en) | 1997-08-27 | 1999-03-03 | Norsk Hydro As | Peptides based on the p21 ras proto-oncogene protein for the treatment of cancer |
| NO309798B1 (no) * | 1999-04-30 | 2001-04-02 | Targovax As | Peptidblanding, samt farmasoytisk sammensetning og kreftvaksine som innbefatter peptidblandingen |
| CN102370974B (zh) | 2002-12-16 | 2014-09-17 | 全球免疫股份有限公司 | 用于免疫治疗的基于酵母的疫苗 |
| US20140199405A1 (en) * | 2013-01-11 | 2014-07-17 | Abraxis Bioscience, Llc | Method for treating cancer based on mutation status of k-ras |
| EP3369432A1 (en) | 2013-12-09 | 2018-09-05 | Targovax Asa | A peptide mixture |
-
2015
- 2015-05-05 CA CA2947963A patent/CA2947963A1/en not_active Abandoned
- 2015-05-05 ES ES15720986T patent/ES2716923T3/es active Active
- 2015-05-05 KR KR1020167034070A patent/KR20170002563A/ko not_active Withdrawn
- 2015-05-05 US US15/308,917 patent/US9757439B2/en not_active Expired - Fee Related
- 2015-05-05 AU AU2015257774A patent/AU2015257774B2/en not_active Ceased
- 2015-05-05 DK DK15720986.7T patent/DK3140320T3/en active
- 2015-05-05 EP EP15720986.7A patent/EP3140320B1/en not_active Revoked
- 2015-05-05 CN CN201580023165.3A patent/CN106414493A/zh active Pending
- 2015-05-05 RU RU2016147527A patent/RU2700929C2/ru active
- 2015-05-05 SG SG11201608712PA patent/SG11201608712PA/en unknown
- 2015-05-05 BR BR112016025764-2A patent/BR112016025764A2/pt not_active IP Right Cessation
- 2015-05-05 MX MX2016014414A patent/MX2016014414A/es unknown
- 2015-05-05 SG SG10201809701TA patent/SG10201809701TA/en unknown
- 2015-05-05 WO PCT/EP2015/059861 patent/WO2015169804A1/en not_active Ceased
- 2015-05-05 JP JP2016565676A patent/JP2017514847A/ja active Pending
-
2016
- 2016-11-01 IL IL248671A patent/IL248671B/en unknown
- 2016-11-04 CL CL2016002794A patent/CL2016002794A1/es unknown
-
2020
- 2020-02-27 JP JP2020032081A patent/JP7304629B2/ja active Active
Also Published As
| Publication number | Publication date |
|---|---|
| RU2016147527A3 (https=) | 2019-01-21 |
| AU2015257774A1 (en) | 2016-12-22 |
| US9757439B2 (en) | 2017-09-12 |
| EP3140320A1 (en) | 2017-03-15 |
| WO2015169804A1 (en) | 2015-11-12 |
| IL248671B (en) | 2021-08-31 |
| US20170065694A1 (en) | 2017-03-09 |
| BR112016025764A2 (pt) | 2018-01-16 |
| CN106414493A (zh) | 2017-02-15 |
| RU2700929C2 (ru) | 2019-09-24 |
| CA2947963A1 (en) | 2015-11-12 |
| AU2015257774B2 (en) | 2018-12-20 |
| JP7304629B2 (ja) | 2023-07-07 |
| CL2016002794A1 (es) | 2017-06-09 |
| KR20170002563A (ko) | 2017-01-06 |
| JP2017514847A (ja) | 2017-06-08 |
| IL248671A0 (en) | 2017-01-31 |
| SG11201608712PA (en) | 2016-11-29 |
| EP3140320B1 (en) | 2018-12-26 |
| RU2016147527A (ru) | 2018-06-08 |
| JP2020100650A (ja) | 2020-07-02 |
| SG10201809701TA (en) | 2018-12-28 |
| DK3140320T3 (en) | 2019-04-15 |
| ES2716923T3 (es) | 2019-06-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2016014414A (es) | Vacuna de peptido que comprende un peptido ras mutante y un agente quimioterapeutico. | |
| MX2021013837A (es) | Enfoque de inmunoterapias de combinacion para el tratamiento del cancer. | |
| MX2018014175A (es) | Conjugados de anticuerpo-fármaco anti-cmet y métodos para su uso. | |
| PH12017500022A1 (en) | Carrier-antibody compositions and methods of making and using the same | |
| PH12016501618A1 (en) | Anti-dll3 antibodies and drug conjugates for use in melanoma | |
| MY187540A (en) | Compounds active towards bromodomains | |
| MX2022001105A (es) | Anticuerpos anti tigit. | |
| HUE049341T2 (hu) | Szubsztituált indazolok, eljárás ezek elõállítására, ezeket tartalmazó gyógyszerkészítmények, valamint ezek alkalmazása gyógyszerkészítmények elõállítására | |
| AU201612434S (en) | Chair | |
| MX370792B (es) | Composiciones para usarse en el tratamiento de cáncer. | |
| MX2017005977A (es) | Anticuerpos biespecificos y metodos de uso en oftalmologia. | |
| MY191539A (en) | Streptococcal vaccine | |
| MX2017005975A (es) | Anticuerpos anti factor de crecimiento derivado de plaquetas b (pdgf-b) y metodos de uso. | |
| MX2022013912A (es) | Procedimientos novedosos para inducir una respuesta inmunitaria. | |
| MX2019005309A (es) | Anticuerpos anti-bag3 en combinacion con inhibidores del punto de control inmunitario para uso terapeutico. | |
| PH12016501434A1 (en) | Compositions for use in the treatment of allergic conditions | |
| MX2017014776A (es) | Combinacion farmaceutica de everolimus con dactolisib. | |
| MA39599A (fr) | Dosage et administration d'agents thérapeutiques anti-egfr | |
| PH12017501979A1 (en) | Pharmaceutical compound | |
| NZ728041A (en) | Substances and methods for the use in prevention and/or treatment in huntington’s disease | |
| TWD174083S (zh) | 電連接器之部分 | |
| IL249483B (en) | Preparation methods for a novel generation of biological safe klh products used for cancer treatment, for the development of conjugated therapeutic vaccines and as challenging agents | |
| HK1242199A1 (en) | Treatment of cancer using tlr9 agonist with checkpoint inhibitors | |
| TWD174084S (zh) | 電連接器之部分 | |
| UA84302U (ru) | Способ коррекции иммунного статуса у больных рекуррентным депрессивным расстройством |